Macrogenics Inc (MGNX): who owns it and who trades it
As of Nov 16, 2026, MGNX insiders reported 1 open-market sale worth $129K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey Stuart Peters (Vice president), with $129K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Macrogenics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MGNX
122 funds and institutions reported MGNX shares worth $226M at the end of Q2 2026, about 77% of the company. The largest holder is Armistice Capital, LLC with 7.9%.
Funds and institutions (13F) 77%Everyone else 23%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.01M | 7.88% | $23.1M | -17% |
| BlackRock, Inc. | 4.68M | 7.36% | $21.6M | +302% |
| Vanguard Capital Management LLC | 2.66M | 4.18% | $12.3M | +0% |
| Renaissance Technologies LLC | 2.63M | 4.14% | $12.2M | -11% |
| Acadian Asset Management LLC | 2.54M | 4.00% | $11.7M | -0% |
| Bank of America Corp | 2.49M | 3.92% | $11.5M | +4% |
| Two Sigma Investments, LP | 2.47M | 3.88% | $11.4M | -2% |
| Millennium Management LLC | 2.37M | 3.74% | $11M | -15% |
| Wasatch Advisors LP | 2.02M | 3.18% | $9.3M | +29% |
| Ra Capital Management, L.P. | 1.86M | 2.93% | $8.6M | No change |
| Vanguard Portfolio Management LLC | 1.82M | 2.86% | $8.4M | +51% |
| Mackenzie Financial Corp | 1.64M | 2.58% | $7.6M | +175% |
| Marshall Wace, LLP | 1.62M | 2.54% | $7.5M | -20% |
| Geode Capital Management, LLC | 1.58M | 2.48% | $7.3M | +126% |
| Affinity Asset Advisors, LLC | 1.22M | 1.91% | $5.6M | +143% |
| D. E. Shaw & Co., Inc. | 1.06M | 1.67% | $4.9M | +0% |
| Jacobs Levy Equity Management, Inc | 1.00M | 1.58% | $4.6M | +127% |
| Connor, Clark & Lunn Investment Management Ltd. | 1.00M | 1.57% | $4.6M | +15% |
| State Street Corp | 863,663 | 1.36% | $4M | +194% |
| Goldman Sachs Group Inc | 558,001 | 0.88% | $2.6M | +104% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MGNX insiders reported $0 of open-market purchases and $129K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Jeffrey Stuart Peters | Vice president | Sale plan | 31,105 | $4.15 | $129K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary | – | $129K | Aug 19, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MGNX short interest
Moderate short interest. 7.8% of MGNX shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 1%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.95M MGNX shares were sold short, 7.8% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.95M | 7.77% | -2% | 1.28M | 3.9 |
| Oct 15, 2026 | 5.06M | 7.94% | -28% | 618,639 | 8.2 |
| Sep 30, 2026 | 7.04M | 11.05% | +0% | 645,909 | 10.9 |
| Sep 15, 2026 | 7.03M | 11.04% | -1% | 447,176 | 15.7 |
| Aug 31, 2026 | 7.12M | 11.19% | -2% | 413,111 | 17.2 |
| Aug 14, 2026 | 7.26M | 11.39% | -1% | 602,630 | 12.0 |
| Jul 31, 2026 | 7.34M | 11.55% | +29% | 786,497 | 9.3 |
| Jul 15, 2026 | 5.69M | 8.95% | -14% | 836,663 | 6.8 |
| Jun 30, 2026 | 6.63M | 10.43% | +38% | 1.92M | 3.5 |
| Jun 15, 2026 | 4.79M | 7.54% | -4% | 562,075 | 8.5 |
| May 29, 2026 | 4.98M | 7.83% | +2% | 951,721 | 5.2 |
| May 15, 2026 | 4.88M | 7.67% | +66% | 1.96M | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Macrogenics company events
Macrogenics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026LeadershipThe Board of Directors of MacroGenics, Inc., upon the recommendation of the Nominating and Governance Committee of the Board, approved an increase in the size of the Board from ten to eleven members. Filing
- Oct 23, 2026AnnouncementMacroGenics, Inc. issued a press release announcing interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 23, 2026AnnouncementOn July 23, 2026, MacroGenics, Inc. issued a press release providing a clinical update on its ongoing Phase 1 study of MGC026. Filing
- Jul 8, 2026LeadershipKaren Ferrante, M.D. provided notice to the board of directors of MacroGenics, Inc. of her decision to resign from the Board, effective September 1, 2026. Filing
- Jul 7, 2026DealMacroGenics, Inc. completed the previously announced sale of certain assets and liabilities related to its GMP manufacturing operations, including its CDMO business conducted by the Company at its manufacturing facility located at 9704 Medical Center Drive, Rockville, Maryland and related warehouse… Filing
- May 20, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- May 12, 2026AgreementMacroGenics, Inc., a Delaware corporation, entered into an Asset Purchase Agreement with Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan, and Bora Biologics USA, LLC, a Delaware limited liability company, pursuant to which the Company agreed to sell to the Purchaser… Filing
- May 4, 2026AgreementMacroGenics, Inc. and an entity affiliated with Sagard Healthcare Partners entered into a First Amendment to the Purchase and Sale Agreement, dated as of June 9, 2025, pursuant to which the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ… Filing
- Apr 8, 2026AnnouncementMacroGenics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has removed the partial clinical hold on the Company’s Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Mar 2, 2026AnnouncementDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Feb 24, 2026AnnouncementMacroGenics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Filing
- Nov 20, 2025LeadershipMacroGenics, Inc. and Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer of the Company, mutually agreed that Dr. Eck would depart the Company, effective as of December 31, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Macrogenics financials
Famous investors that hold MGNX
5 of the 50 well-known investors we track reported holding MGNX in their latest 13F filing. The largest position is Jim Simons's, worth $8.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.18M | $8.4M | 0.0% | -17% |
| Israel Englander · Millennium Management | Q3 2026 | 1.20M | $4.6M | 0.0% | -50% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 585,493 | $2.3M | 0.0% | +226% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 100,870 | $389K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 90,676 | $350K | 0.0% | +455% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MGNX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.4% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.4% |
Questions about Macrogenics Inc (MGNX) stock
Who owns the most MGNX stock?
The largest reported owner of Macrogenics Inc (MGNX) is Armistice Capital, LLC, with 7.9% of the company. In total, 122 funds and institutions reported holding MGNX at the end of Q2 2026, together about 77% of the shares. See the largest owners.
Are MGNX insiders buying or selling?
In the last 12 months, MGNX insiders reported no open-market purchases and 1 sale worth $129K. The latest trade was on Aug 19, 2026. See every trade.
What is the short interest in MGNX?
As of Oct 30, 2026, 4.95M MGNX shares were sold short, 7.8% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold MGNX?
5 of the 50 well-known investors we track reported MGNX in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $8.4M. See all holders.
Executive pay
Macrogenics's chief executive was paid a total of $6.4M for the year ended Dec 31, 2024, up 73% from $3.7M the year before. In the last 12 months, Macrogenics's executives and directors bought no stock on the open market and sold $129K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.